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Introduction
The past several decades have seen rapid and extensive
changes in the practice of cardiology, especially in the
innovation and utilization practices of imaging, interven-
tional, and electrophysiology procedures. Enhanced radio-
nuclide imaging techniques, evolution of echocardiography,
development of cardiac magnetic resonance (MR), and
coronary computed tomography (CT) angiography tech-
niques, as a well as drug-eluting stents and cardiovascular
implantable electronic devices, have revolutionized how
patients are diagnosed and treated. Although these devel-
opments have resulted in direct patient benefits including
improved survival and enhanced quality of life, there has
been an accompanying increase in resource utilization and
healthcare costs. Although declines in utilization of many
cardiovascular procedures have been observed as of late,
during the years preceding 2005, the growth rates were at
times substantial as these technologies were adopted. The
perceived high rate of growth of expenditures related to
cardiovascular procedures has precipitated payers to initiate
utilization constraints to markedly reduce spending and
reimbursement. Various payer initiatives have created an
onerous burden leading to costly administrative require-
ments, including physician profiling and prior authorization
(1). These general programs are also, in part, driven by
marked geographic variability in utilization, which under-
score the need for further guidance regarding optimal
patient selection for procedures (2,3). Professional efforts to
better define quality have identified the importance of
matching procedures and patients (4).
In response to the imperative for improving the utiliza-
tion of cardiovascular procedures in an efficient and con-
temporary fashion, the American College of Cardiology
Foundation (ACCF), along with imaging subspecialty so-
cieties and other organizations, developed the first set of
Appropriate Use Criteria (AUC) in 2005, focusing on
indications for radionuclide imaging (5). A concurrent
publication defined in some detail the methods involved in
the construction of these criteria (6). During the ensuing 7
years, there have been numerous other AUC publications
(Figure 1)—including revisions to several of the original
criteria—that reflect expansion of the AUC concept and
advances within the specific disciplines, as well as method-
ological changes. The aim of the current paper is to review
recent modifications in the methods for developing AUC,
most notably substantial alterations in the nomenclature
employed for appropriateness categorization (detailed later
in the text).
Although the methods for AUC construction have
evolved, the core process remains rooted in the application
of the validated, prospectively based modified RAND Ap-
propriateness Method (7,8) as was described in the initial
methods article (6). Readers interested to learn more about
the RAND method and adaptations developed by ACCF
are encouraged to review these papers, as well as the current
paper. Because the RAND method offered a general ap-
proach to constructing criteria, most of the approaches
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interpretations required for implementation rather than
changes to the basic framework of the RAND approach. As
such, to address the feedback of the clinical cardiologists,
other patient-care professionals, payers, and regulators, the
ACCF AUC Task Force (formerly the Appropriateness
Criteria Working Group) has refined its methods over time.
The basic methodology is shown in Figure 2. This paper
provides an update describing the various revisions that have
improved the rigor and consistency of the AUC develop-
ment process. A comparison of the major changes between
the original and updated methods is summarized in Table 1.
Additionally, this paper describes the modifications in methods
designed to facilitate the creation of multimodality AUC, an
initiative aimed to summarize, in 1 document, current recom-
mendations regarding multiple procedures. A brief summary of
studies examining the AUC process and their evaluation and
implementation to date is also provided.
Defining Appropriate Use
In the first series of AUC documents, there was strict
adherence to the terms of appropriateness established by
RAND methodology, including the title, “appropriateness
Figure 1. Timeline of ACCF AUC Development, Including Current P
ACCF  American College of Cardiology Foundation; ACR  American College of Rad
cardiography; ED  emergency department; HF  heart failure; IHD  ischemic hea
coronary revascularization; RNI  radionuclide imaging; SPECT MPI  single-photoncriteria” (6–8). More recent documents have adopted theterm “Appropriate Use Criteria.” This change reflects the
more active function of the AUC in promoting evidence-
based, effective use of cardiovascular technologies. Another
change since the first publication of AUC has been the
expansion of this initiative from imaging to devices and
procedures including coronary revascularization, diagnostic
catheterization, implanted cardiac defibrillators, and cardiac
resynchronization devices. Although imaging remains a critical
focus of the AUC, the ACCF recognizes that there is a need
to address the clinical applications of the appropriate utilization
of all cardiovascular procedures. In response, the AUC Task
Force has expanded the list of potential topic areas.
The definition of appropriate use is largely consistent across
technologies and procedures, and includes consideration of
benefits and risks; although specific definitions for terms and
surrounding assumptions are modified based on the most
clinically relevant aspects. The basic definition states:
An appropriate diagnostic or therapeutic procedure is one in
which the expected clinical benefit exceeds the risks of the
procedure by a sufficiently wide margin such that the procedure
is generally considered acceptable or reasonable care.
For diagnostic imaging procedures, benefits include incre-
mental information, which when combined with clinical
e of Documents in Development
; CT  computed tomography; Dx Cath  diagnostic catheterization; Echo  echo-
ase; MR  magnetic resonance; PVD  peripheral vascular disease; Revasc 
ion computed tomography myocardial perfusion imaging.ipelin
iology
rt disejudgment augment efficient patient care, weighed against
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tential hazard of missed diagnoses, radiation, contrast,
and/or unnecessary downstream procedures).
For therapeutic procedures such as revascularization or
implanted cardiac defibrillator/cardiac resynchronization
therapy, the benefits include survival or health outcomes
(such as improved symptoms, functional status, and/or
quality of life) weighed against the risks of the procedure
and subsequent related care.
These definitions may vary slightly but always emphasize
whether a test or procedure is a reasonable care option for
the population of patients described by the indication after
consideration of benefits and risks.
Terminology Clarifications
The specific terminology used to define appropriate proce-
dural utilization has been discussed extensively since the
publication of the first AUC document by ACCF. The
intent of the AUC effort was to focus on patient popula-
tions, case mix over time, and quality improvement while
informing, but not dictating, care for individual patients.
The 3 categories were meant to reflect a continuum of
benefits and risks to various patient populations. However,
the categorical nature of AUC inherently placed individual
patient cases into 3 distinct groups that were often viewed as
absolute. Unfortunately, AUC efforts to describe the relative
proportion of patients who might or might not benefit from
a procedure over time were obscured by concern over how
individual cases would be adjudicated. Such interpretation
often led to misperceptions by all stakeholders about when
a procedure may be considered for a patient. For instance,
Figure 2. Schematic Diagram of Methodology for ACCF Appropriat
Overall, more than 50 professionals are involved in the creation of each AUC docum
Adapted from Patel et al. (6).should procedures classified as Uncertain but still used beconsidered questionable care choices? Should procedures
categorized as Inappropriate always be avoided or could
there be mitigating circumstances in an individual patient
making the procedure a reasonable choice? Should all
procedures that are classified as Appropriate be performed
in patients or may some patients go without the procedure?
In order to address these issues, the AUC Task Force
surveyed numerous stakeholders to consider clarifications to
the terminology during the summer of 2012. The feedback
suggested a change to the terms was necessary, as the
current AUC terminology was unable to properly commu-
nicate the goals of each stakeholder in a consistent fashion.
The result was a recommendation by the AUC Task Force
to modify the terms and clarify the definitions. The updated
terms and definitions more closely reflect their application
in practice, including an expected distribution between each
AUC category for every population, methods for document-
ing exceptions, and proper application to individual pa-
tients. These changes reflect the continued commitment by
the AUC Task Force and the College to measuring,
benchmarking, and improving the appropriateness of pro-
cedures for patients while reducing use in populations who
will rarely benefit. As such, the contemporary, revised
definitions for the 3 categories described by Appropriate
Use documents herein will be the following:
Median Score 7 to 9: Appropriate Care
An appropriate option for management of patients in this
population due to benefits generally outweighing risks;
effective option for individual care plans although not always
e Criteria Document Developmente Us
ent.necessary, depending on physician judgment and patient
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and is generally reasonable for the indication).
Median Score 4 to 6: May be Appropriate Care
At times, an appropriate option for management of patients
in this population due to variable evidence or agreement
regarding the benefits/risks ratio, potential benefit based on
practice experience in the absence of evidence, and/or variabil-
ity in the population; effectiveness for individual care must be
determined by a patient’s physician in consultation with the
patient based on additional clinical variables and judgment
along with patient preferences (i.e., procedure may be accept-
able and may be reasonable for the indication).
Median Score 1 to 3: Rarely Appropriate Care
Rarely an appropriate option for management of patients in
Table 1. Summary Comparison of Differences Between Origina
Original Methods
Name of Document
● Appropriateness Criteria
Appropriateness Topics
● Cardiovascular imaging
Appropriateness Terms
● Appropriate, Uncertain, Inappropriate
● Short definitions
Process
Step 1: Indication Development and Literature Review
Writing Group
● Parent task force served as the writing group and developed
indications
External Review of Indications
● Ad hoc review by a few individuals
Step 2: Rating Panel Composition (previously Technical Panel)
Number of Panelists
● Any number
Balance of Rating Panel Expertise
● General balance of different experts; no specific limitations on members
specific expertise or orientation
● No formal survey of expertise; collection of CVs only
Use of Prior Documents
● Instructed not to consider prior documents
Step 3: Rating Panel Process
Roles of Facilitator, Writing Group, and Methodologist
● Appointed facilitator and selected task force members
provide writing group and methods expertise
Standardized Rating Package
● No standardized listing of rating package components
Step 4: Rating Tabulation
Understanding Agreement and Disagreement
● BIOMED Concerted Action definition usedthis population due to the lack of a clear benefit/riskadvantage; rarely an effective option for individual care
plans; exceptions should have documentation of the clinical
reasons for proceeding with this care option (i.e., procedure
is not generally acceptable and is not generally reasonable
for the indication).
Although the definition of Appropriate generally has
been an effective and widely accepted term, concerns exist
that use of the term may stimulate overuse of a procedure in
whom alternative management strategies may exist. The task
force continues to emphasize that an Appropriate procedure is
a reasonable option but may not uniformly be necessary for
such patients. AUC do not supplant the need to formulate
decisions with individual patients. Necessity reviews have been
undertaken by RAND to determine when procedures rated as
appropriate are required. Although important, ACCF AUC
has not undertaken such reviews to help define areas of
Updated Methods
Updated Methods
● Appropriate Use Criteria (AUC)
● All cardiovascular technologies and procedures
● Appropriate, May be Appropriate, Rarely Appropriate
● Expanded definitions including population application and how AUC
inform individual procedure decisions
● Up to 10 experts appointed by multiple societies develop indications
● Task force liaison appointed
● Indications written to harmonize with prior AUC documents
● Extensive review by up to 50 experts appointed by multiple
societies, with subsequent integration of comments
● Odd number required
● Explicit balance of 50% engaged primarily in technology
under evaluation
● Survey of expertise to evaluate panel balance
● Prior AUC documents explicitly included
● Pre-assigned roles of non-expert facilitator/moderator, writing
group liaison, and methodology expert from task force
● Formal components of rating package include preamble,
instructions, assumptions, definitions, indications,
guideline/indication mapping, and evidence tables/references
● For larger panels, interpercentile range adjusted for symmetry usedl and
withpotential underuse, but ACCF and the American Heart
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performance measures are well suited for addressing such
questions.
All of the AUC publications have emphasized that
patients in the Uncertain category may be reasonable can-
didates for the procedure. The task force continues to
emphasize that this category represents a patient population
for whom individual care must be determined by the
physician working directly with the patient. Although
additional research may at times help contribute to future
understanding of procedure use in this population, the
current state of science and clinical experience indicates that
physicians and patients may consider the procedure among
care options for this population. As such, this rating should be
not be used as the primary basis for denying coverage and
reimbursement. This understanding has been emphasized and
included in the deliberations of each rating panel. To address
these issues, as well as to obviate any ambiguity associated with
the term, the task force has determined that future published
AUC will replace the term Uncertain with May Be Appropriate.
As mentioned in the preceding text, concerns have been
raised indicating substantial misperception related to the
term Inappropriate, even though this term was extracted
directly from the UCLA/RAND methodology. The intent
of the term was related to practice patterns, which allows for
a small percentage of Inappropriate use (6). Unfortunately,
misunderstanding has been present regarding this category
as it applies to individual cases and AUC patterns of
organizations and physicians over time. The inherent limi-
tation of the AUC are the attempt to categorize individual
patients with 3 to 4 simple characteristics, which serve well
for a population but may not capture specific individual
patients. For these patients, the AUC have consistently
emphasized the need to document these differences while
avoiding overuse of the procedures in these patient popula-
tions. Therefore, the AUC Task Force has substituted the
term Rarely Appropriate for the previous term Inappropriate.
However, physicians should be aware that procedures in this
category should have unique individual patient circumstances
that are documented to justify their use, and be especially
cautious to avoid procedures that, in clinical guidelines, indi-
cate potential patient harm if the procedure is performed.
Appropriate Use Criteria Development
Process Revisions
Step 1: Topic Selection, Nomination Process, and
Writing Group Composition
Topics are selected by the AUC Task Force after careful
review of the current variation in utilization, stakeholder
needs, procedure volume and cost, available evidence, and
feasibility. Input is uniformly sought from ACCF councils
and committees, cardiovascular and imaging specialty soci-
eties, noncardiologists, and relevant stakeholders such as
health payers, policymakers, and patients. Although in someinstances, AUC development can provide a logistical frame-
work for the implementation of evidence synthesized by
clinical practice guidelines, AUC are often of particular
importance when gaps in the medical literature, clinical
evidence, or guidance publications are present. In particular,
the AUC are aimed at guiding both diagnostic and thera-
peutic procedures based upon specific, commonly encoun-
tered clinical scenarios, many of which cannot be studied in
randomized trials. The AUC Task Force fosters up-to-date
guidance that encompasses the collective expert opinion of a
multidisciplinary group of clinical, payer, policy, and other
stakeholders. In other words, AUC are both evidence-based
and utilize expert consensus. Nominations for the writing
group, reviewers, and the rating panel are solicited from a
broad set of partnering organizations and societies and
selected by the task force in consultation with partnering
societies and the writing group. Relationships with industry
and intellectual bias based on clinical and professional expertise
is considered during the nomination and selection process.
Further information about relationships with industry can be
found on page 14, and a discussion of the composition of the
groups can be found within each of the group descriptions on
the following pages.
The writing group composition has evolved over time but
continues to include members with significant professional
expertise and to broadly represent multiple stakeholders. In
contrast to the initial AUC documents’ writing groups that
were predominantly composed of members from the AUC
Working Group, writing groups are now composed of 6 to
10 members from multiple societies and diverse organiza-
tions, allowing for broader representation across disciplines.
A substantial portion of writing group members remain
experts in the technique under consideration to ensure that
indications are constructed to capture the clinical applica-
bility and limitations of the technologies or therapy under
consideration.
Further, an AUC Task Force member is now appointed
to each writing group to serve as a liaison to provide
methodological and operational oversight. The full AUC
Task Force also serves to review and approve relevant
clinical indications, review literature summaries, provide
guidance on methodological issues, ensure harmonization of
indications, definitions, and assumptions across AUC doc-
uments, whenever possible, and to foster finalization of the
AUC documents in a time-efficient fashion.
Step 2: Indication Development and Literature Review
Substantial effort has been made to standardize the wording for
the clinical indications, assumptions and definitions as they
span different documents for the various modalities/
procedures.
Clinical Indications
As clinical indications or scenarios are developed, consis-
tency, clarity, and utility are emphasized to support a
foundation for meaningful evaluation. Whenever possible,
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structured approach, when applied to cardiac imaging,
commonly includes construction of tables for patient diag-
nosis and risk assessment, current symptomatology, prior
testing, previous revascularization, evaluation for a change
in clinical status, and consideration of special clinical cir-
cumstances. At times, additional groups of scenarios may be
included, such as the use of routine surveillance testing
either early or late after a procedure or test. The AUC
increasingly attempt to address such scenarios, recognizing
that the clinical trial evidence base is often quite limited
and, given the cost, may never be achievable in the current
healthcare environment. AUC seek to establish widespread
consensus around the timeframes during which such testing
is unlikely to yield important clinical information. Although
initially it was felt that the AUC should not attempt to be
all-inclusive but rather focus on common, real-world situa-
tions; external feedback regarding the early AUC docu-
ments highlighted gaps in indications or unclear clinical
scenarios. The AUC Task Force responded to this feedback,
by significant expansion and revision of the indications in
Figure 3. Example of Hierarchy of Potential Test Ordering Based o
isk Assessment of Ischemic Heart DiseaseCABG  coronary artery bypass graft surgery; CV  cardiovascular; PCI  percutaneous cosubsequent documents (9). The ensuing applications of
revised AUC are reflective of this expansion, noting that the
added indications have markedly improved the utility of the
documents (10).
When possible, AUC now provide a hierarchy of indica-
tions to guide use of the AUC in a systematic fashion,
tailored for each modality, and assist in applying a particular
clinical situation to 1 of the indications, an example of
which is depicted in Figure 3. This approach also greatly
facilitates AUC evaluation and implementation, as it per-
mits an ordered and reproducible way to apply AUC.
The assumptions present within the AUC have been
broadened over time to assist in implementation and are
aimed at issues such as the competency to perform proce-
dures, inclusion criteria, exclusion criteria including consid-
eration of common contraindications, standard protocols,
and understanding of common procedure risks. For exam-
ple, the details regarding the structure and performance of
the imaging laboratory, catheterization laboratory, or oper-
ating suite are now more explicit, as these are likely to be
included in evaluation for accreditation. These assumptions
nical Presentation for the Detection andn Clironary intervention; Pre-op  pre-operative.
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baseline so that the rating is based upon clinical issues rather
than variability in competence, test quality, or other issues.
Although important, these issues are beyond the scope of
AUC.
Definitions
Commonly used terms and scenarios, such as “ischemic
equivalent,” are used consistently across documents and
have been redefined for improved clarity (10–12). For
example, the incorporation of electrocardiographic abnor-
malities as a clinical finding in the definition of an ischemic
equivalent now permit extension of this indication beyond
symptoms. In addition, assessment of risk in asymptomatic
individuals has been modified to reflect the concept of
global risk, which may be based on any of the major
literature-based risk scores, including the Adult Treatment
Panel III, modified Framingham risk, or the Reynolds’s
score, to incorporate the most recent data and include items
such as family history in the evaluation (10–12). In fact, the
AUC has helped to highlight the need for better definitions
and methods around risk stratification, pre-test probability,
and findings from noninvasive tests.
To ensure consistency across AUC as well as other
guidance documents, the task force relies heavily on ACCF/
AHA Clinical Practice Guidelines for many of its defini-
tions and assumptions. Additionally, the task force, has had
a continued dialog with the Clinical Practice Guidelines
Task Force to ensure harmonization.
Guideline Mapping and Evidence Review
Once the clinical indications are developed, a table mapping
the indications to recommendations of other guidance
documents, in particular ACCF/AHA practice guidelines,
is constructed to preserve and encourage agreement across
various clinical policy documents as related to the specific
AUC technology being evaluated. Practice guidelines often
contain a comprehensive summary of the available literature
and serve as the primary source of evidence review for the
AUC process. As these guidelines are updated, the writing
groups are instructed to update the assumptions, indica-
tions, and definitions accordingly. New guidelines, such as
the pre-operative guidelines (13), are incorporated into the
AUC as they are written and revised, often resulting in
changes in the wording of clinical indications. For evidence
not covered by the Guidelines, the writing group assembles
the most up-to-date scientific evidence as it may relate to
the topic and specific clinical indications.
Rating Panel Materials
After these various components have been drafted, a stan-
dardized literature review and ratings package is prepared by
each writing group following a pre-set template. The
template includes a preamble, instructions on the rating
process, definitions, assumptions, abbreviations, indication
tables, and evidence/guideline mapping tables. These items
are then reviewed and approved by the parent AUC TaskForce. The task force and writing committees have contin-
ually expanded and clarified these materials, providing
supportive documentation sufficient for reviewers to provide
feedback and the members of the rating panel to render a
score on each clinical scenario that is reflective of the current
evidence base.
Step 3: External Review of Clinical Indications
Subsequent review of the indications by the AUC Task
Force and external peer reviewers is aimed at further
improvement of the definitions of the clinical scenarios.
This was previously done by an ad hoc group of experts, but
this process has now been formalized to include a detailed
external review by representatives from key participating
medical specialty societies, as well as those representing
health services research and those with familiarity with
clinical practice guidelines and other key stakeholder’s
policies. This often involves more than 40 individuals in the
review of the draft set of indications. This process is crucial
to indication development, because revisions are not allowed
following final rating panel voting, as this would violate the
basic tenets of the modified Delphi methodology.
Step 4: Panel Rating
Rating Panel Composition
The AUC Task Force has always attempted to maintain a
balance on the rating panels (previously referred to as the
technical panel) of specialists using the technology and
other professionals who are referrers, general cardiologists,
outcome specialists, and/or generalists who care for germane
patient populations, as well as the payer community. Over-
all, a diverse panel composition ensures the production of
balanced, equitable, and reproducible ratings (6–8). Spe-
cialists whose key area of interest is the primary focus of the
AUC are a minority of rating panel members. A survey of
practice experience is sent to all rating panel members
before formalizing their appointment to the panel. This
information is used to ensure that the task force and writing
group, who determine the composition of the rating panel,
are able to consider an accurate description of the individ-
uals’ expertise, interests, and relationships before selection
to serve on the panel. This approach has been recently
challenged by some who believe that the rating panel should
be composed either exclusively or by a majority of specialists
within the field under evaluation, stating the view that such
subspecialists have a unique and greater understanding of
the field (14). However, the AUC Task Force believes that
AUC should be as evidence-based as possible and that all
members of the rating panel should be able to determine the
balance of clinical benefits and risks of a particular proce-
dure or technology based on practice experience and rele-
vant literature, especially when provided with evidence
tables and practice guidelines. In addition, such nonexpert
individuals often represent the community of practitioners
ordering the test or procedure and provide an important
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use of a majority of “nonspecialists” within a rating panel
permits a diversity of perspectives and enhances external
credibility.
After using an even number of panel members on the first
AUC, which required rounding to determine the final
median score and resulting AUC category, the task force
decided that all rating panels must be composed of an odd
number of individuals so that the final median score reflects
the whole number score of an actual rating panel member.
Initial Panel Ratings and Meeting
The first round of indication ratings are performed inde-
pendently by each rater. Following this, participation in a
face-to-face meeting is required. In addition to the panel
members, the AUC Task Force has standardized specific
roles for several other individuals during this meeting. A
moderator who has not been involved in indication con-
struction establishes the goals, procedural rules, and facili-
tates the meeting. This individual typically does not partic-
ipate in rating the specific technology or procedure under
review and does not practice the procedure being reviewed.
The moderator may serve as an alternate panel member if
unforeseen circumstances prevent a panelist from complet-
ing the process. During the face-to-face meeting, the
writing group liaison member is also present to answer
questions specific to the indications and to assist in any
modification or clarification of indications recommended by
the rating panel. Lastly, a member of the AUC Task Force
is present specifically to address methodological issues as
they pertain to the AUC.
During the rating panel meeting, a standardized presen-
tation is given providing an overview of the AUC develop-
ment process and a review of the assumptions and defini-
tions along with an outline of the indication tables and key
clinical parameters used in the document. The panelists are
provided with their own votes and a tabulation of all votes
presented in an anonymous fashion. All indications are
discussed using a “round robin” discussion style to ensure all
panel members have the opportunity to lead and participate
in the discussion. Particular attention is paid to indications
with widely divergent ratings to ensure that there is a
uniform understanding of the clinical scenario. Following
the face-to-face meeting, the panelists then independently
rescore all indications. In a very few cases in which there is
a wide dispersion of scores and where further indication
rewording would better align the indication with evidence
and/or practice experience, a third rating of the specific
indication(s) in question may be undertaken. The median
score for each clinical scenario becomes the final indication
rating.
Final Rating Tabulation
The final scores are reported in discrete categories (Appro-
priate, May Be Appropriate, and Rarely Appropriate—as
well as with the numerical median rating, with anonymized
individual scores available in an online appendix).In addition to the final indication score, all indications are
assessed to measure the level of agreement among the panel.
When the number of rating panelists is less than or equal to
15 members, the definitions for agreement from BIOMED
Concerted Action on Appropriateness are used, as previ-
ously described (6,8). For panels with more than 16 mem-
bers, this definition is applied first, but a second statistical
method described in the RAND Appropriateness Method
(7) is also applied. Both measures examine dispersion in the
ratings and identify whether most ratings are near the final
median (agreement) or clustered at opposite sides of the
rating scale (disagreement). By definition, indications la-
beled as having disagreement would automatically become
May Be Appropriate. However, to date, no indication has
been qualified under this designation that was not already
uncertain.
Multimodality Appropriate Use Criteria
The original methods paper (6) discussed the expectation
that an evaluation of the efficient use of technology among
alternative technologies or procedures would have to be
considered in the future across similar clinical indications. It
was recognized early on that this would likely be necessary
for noninvasive cardiovascular testing and other procedures,
such as coronary angiography and revascularization, and
other interventional therapeutic procedures.
Coronary Revascularization
The AUC Task Force made a first attempt at such an
evaluation in the Appropriateness Criteria for Coronary
Revascularization (15). The writing group first discussed the
variables essential for the consideration of any form of
coronary revascularization. This led to the framework for
the clinical indications categorized by several domains:
acuity, prior bypass surgery status, presenting symptoms,
ischemia severity on noninvasive testing or fractional flow
reserve, and coronary anatomy, as well as adequacy of
medical therapy. The rating panel was then asked to rate
each indication for the appropriateness of coronary revas-
cularization, independent of the mode (either percutaneous
coronary intervention or coronary artery bypass graft sur-
gery). In a select set of clinical indications with a high
burden of ischemia and/or coronary artery disease, each
procedure (percutaneous coronary intervention and coro-
nary artery bypass graft surgery) was then rated separately. A
separate table presented the relative appropriateness of each
procedure for this limited set of indications.
Diagnostic Testing and Cardiovascular Imaging
A document in progress will focus on multiple tests used to
evaluate patients presenting with signs and symptoms sug-
gestive of coronary artery disease or follow-up of known
coronary disease. This AUC will continue the ongoing
process of establishing similar assumptions, definitions,
evidence synthesis, and clinical indications for several tests
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a given clinical indication/scenario.
This multimodality AUC will evaluate clinical scenarios
that are similar and often identical to those published in
prior AUC documents. However, it will also include testing
techniques not previously covered, such as: exercise tread-
mill testing, so as to include the entire spectrum of cardiac
testing for ischemic heart disease. One key aspect of this
work is that only the category of appropriate use will be
reported rather than a numerical value. The 1 to 9 values
used in the AUC development process are used as a guide to
help rating panels put procedures into the 3 categories. The
rating panel is asked to provide a numerical value corre-
sponding with their final desired category for the procedure.
The wider range of numerical values provides individual
raters with the ability to grade the procedure on a contin-
uum, thus allowing raters with slightly different viewpoints
to dialog but also allow the final ratings to converge into a
single message. Given the potential minor variability across
a rating panel in their final scores within a category, the
numerical scores are less reliable. All raters understand it is
the final categories that describe more generally how often
the procedure will be considered. Therefore, numerical
values should not be used to apply gradations and compar-
isons between procedures scored in the same category.
Central to the rating in this document will be an evaluation
of whether any test is needed and if true differences in
appropriate use of different tests are present for specific
patient populations. Although 1 goal of this document
could have been to determine the ranking of one modality
versus the others, there is limited comparative evidence for
specific imaging modalities. As such, comparative ranking
of tests within an appropriateness category is not the focus
of this document beyond known limitations of specific tests
for certain populations that may result in different appro-
priate use categorizations. In most cases, it is anticipated
that the clinician may have his/her choice of several Appro-
priate procedures or that several will be rated as May Be
Appropriate or Rarely Appropriate. Beyond the ratings in
this document, clinicians may selectively identify proce-
dures/scenarios where other secondary considerations may
apply for specific patients, including safety, cost, local
expertise, availability, patient preference, and so on.
Relationship With Clinical Practice
Guidelines and Other Clinical Policy
Consistency of the AUC with clinical practice guidelines is
critical to avoid confusion on the part of healthcare practi-
tioners and payers. As mentioned previously, before the
rating of the indications, the AUC Task Force and each
writing group emphasize the need for harmonization among
recommendations for tests and procedures, which is enabled
through the construction of guideline/indication mappingtables, references, and careful review during the develop-
ment process.
Within the ACCF, the Science and Clinical Policy
Committee is charged with ensuring communication and
collaboration among key documents and standards develop-
ment groups, such as the task forces and committees for
expert consensus documents, clinical practice guidelines,
AUC, data standards, and performance measures. An open
dialog among members of these groups is necessary to
ensure that the ACCF maintains the strengths of each
document type while promoting collaboration to ensure
consistency and complementary work products. A paradigm
of how these documents interrelate has been proposed (16).
Relationships With Industry and
Other Entities
Although AUC are not prescriptive, they do define the
appropriateness of technology. The ACCF and the AUC
Task Force have focused considerable attention on avoiding
real or perceived relationships with industry and other
entities (RWI) that might impact the rating of a test/
procedure for a specific application. In addition to full
disclosure of all RWI by all individuals involved with the
document, AUC documents are governed by a policy
mandating that the writing group chair and fewer than 50%
of the rating panel have relevant relationships with industry.
The writing group itself is not required to have fewer than
50% without RWI, as it does not participate in the rating of
the indications (17).
The task force determined a modification of what consti-
tutes relevant RWI was necessary for the writing group because
of the unique role of AUC and the multiple groups of
individuals that are involved in the document development
process. In addition, the rating panel is balanced for many
factors, including clinical and professional bias, as has already
been described in the preceding text, further strengthening the
range of viewpoints reflected in the AUC.
Implementation and Evaluation
Publication of the AUC is not the final step towards optimal
utilization of diagnostic and therapeutic techniques. As
demonstrated in Figure 2, the process of AUC construction
itself is iterative, building on published evidence, expert
consensus, past experience, feedback, and new medical
literature and guidelines. Additionally, information gar-
nered from the measurement of appropriateness of actual
use in the community provides guidance in the construction
of new or revised AUC (9,18).
To ensure optimal utilization of diagnostic and therapeu-
tic techniques, measurement of appropriate use in “real-
world” clinical practice based on AUC is necessary to assess
practice performance, to provide direction for educational
and continuous quality initiatives efforts and to provide
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growing number of publications have focused on the eval-
uation of appropriateness of use of technology, highlighting
potential targets for education and utilization improvement
(19,20).
Although most of these studies have involved retrospec-
tive chart review, it is clear that the evaluation of appropriate
use is possible and more actionable when AUC are incor-
porated as a decision support tool in the evolution of
electronic health records and web-based programs. Several
studies also are now available regarding prospective appli-
cation of appropriate use as well whether their utilization
promotes improved patient-centered outcomes and/or effi-
ciency within the diagnostic work-up (21–24).
In this light, a hierarchical structure is generally needed so
as to clearly and reproducibly assign each case to a specific
AUC scenario. To this end, AUC writing groups are now
being encouraged to develop standardized ordering sheets
and design patient care algorithms to summarize the indi-
cations (10–12). The uniform and consistent documenta-
tion of AUC in clinical practice will greatly assist in the
validation of AUC as well as in the potential development of
quality metrics for laboratory or physician standards of
appropriate use. To further support this important direc-
tion, the ACCF/AHA recently developed a methodology
for the creation of a new form of quality metric, termed
“appropriate use metrics” that is based heavily on the
development of performance measures (25).
Utilization management companies and private health
plans have often cited the AUC as justification for their
coverage and review policies. However, many of the pro-
grams are applied to individual cases without consideration
of patterns of care over time for a physician/practice or
feedback regarding performance. As such, these programs
violate the spirit of AUC that are designed to inform care
decisions but are best measured over a patient population
rather than rigidly adjudicating care for individual patients.
Clinicians have at times suggested that AUC do not
sufficiently reflect the realities of clinical practice and sug-
gested that, as a result, the AUC are not valid. The task
force encourages informal feedback and more formal studies
to help improve the criteria while supporting clinical judg-
ment needed for individual patient care. Decision making
should be guided, but not dictated, by AUC. Some proce-
dures rated as Rarely Appropriate should still occur. Other
procedures rated as Appropriate may be reasonable to forgo.
Importantly, AUC should be used to assess the overall
patient mix undergoing procedures and help physicians
tabulate the proportion of patients under their care who fall
into each AUC category and clinical indication, and bench-
mark it to others’ data. By using the AUC to better
understand practice patterns, physicians can engage in
educational discussions with peers and patients about the
important clinical variables and patient-specific characteris-
tics that underpin current procedure use. This information
can be used to adapt to changes in patient mix over time thatcan help to optimize the selection of patients for a given
procedure based on the benefit and risk thresholds of each
physician and patient.
Conclusions
The refinements to AUC methodology, presented in this
paper, reflect the responsiveness of the ACCF and its AUC
Task Force to queries from the clinician and payer commu-
nity for a fair, evidence-based, and practical means to guide
procedural utilization. Current revisions to the AUC meth-
odology have strengthened the clinical relevance of these
documents that are carefully constructed yet continue to
undergo evolution to meet the needs of contemporary
practice patterns and the developing evidence base within
cardiovascular medicine. The focus of AUC is to encourage
optimal patient care by the professional stewardship of
technology utilization within cardiovascular medicine. The
effort aims to join with all cardiovascular practitioners and
stakeholders in providing the optimal clinical decision
making to foster high quality of cardiovascular care for their
patients, and to work toward patterns of care that promote
appropriate utilization and minimize use that lacks sufficient
value whenever possible. These documents have been wel-
comed by many in the cardiovascular community, including
physicians, patients, and policymakers, and have been in-
corporated into processes of clinical care, including educa-
tion, accreditation, and quality improvement programs.
Additionally, the AUC now seem to be having an impact on
performance of tests in certain patient populations, with the
goal of substantial reduction in waste due to unnecessary
tests and procedures. The result is that patients may be more
likely to benefit from cardiovascular technology using pro-
cedures selected for having the potential to favorably impact
patient outcomes; however, there are very limited data to
support such a claim at this time. Just as pharmacological
agents are increasingly targeted toward specific biological
actions and patient genetic markers that are meaningful to
treatment to produce greater benefit at lower risk, tests and
procedures are more effective when matched to patients who
have specific clinical markers suggesting higher benefit to
risk. Nevertheless, the AUC intent is as a guiding docu-
ment; the final decision to proceed with testing or a
procedure remains at the bedside where patient–physician
interaction simply cannot be universally policy-based and
must be done in the context of a discussion about treatment
and patient goals, which is never a black or white decision.
The refinements to AUC methodology, presented in this
paper, reflect the AUC Task Force’s commitment to adapt
and respond to the ever-evolving needs of cardiovascular
practice. Over time, the task force continues to focus on
reflecting the evolution of contemporary practice patterns
and accruing scientific evidence. The AUC Task Force
remains steadfast in its aim to ensure a patient-centered, profes-
sional stewardship of technology application within cardiovascular
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holders—including patients, cardiovascular specialists, primary
care physicians, and other specialists, and regulatory and payer
bodies—in support of optimal clinical decision making and
ensuring high-quality, cardiovascular care.
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